GALT 4.16 Galectin Therapeutics Inc $GALT Hit a 52
Post# of 61
Posted On: 11/20/2014 11:22:21 AM
GALT 4.16 Galectin Therapeutics Inc $GALT Hit a 52 week low of 4.01 Closing the day 10:45 at 4.16 -0.18 -4.15% With a day low of 4.01 and a total volume of 119,659.
GALT Recent Posts: http://investorshangout.com/Galectin-Therapeu...ALT-61936/
GALT Galectin Therapeutics Inc Recent Headline News
Galectin NASH treatment meets primary endpoint in Phase 1
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:12AM CST
GALT: 4.18 (-0.16)
Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program
GlobeNewswire - Mon Nov 10, 7:43AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third quarter and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission. The Company also provided an update on its development program.
GALT: 4.18 (-0.16)
Galectin Therapeutics beats by $0.10
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:25AM CST
GALT: 4.18 (-0.16)
Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development
GlobeNewswire - Sun Nov 09, 2:30PM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, presented data today from the Company's Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis at The Liver Meeting in Boston, Massachusetts. Stephen A. Harrison, MD, Chief of Hepatology at Brooke Army Medical Center in Fort Sam Houston and a clinical trial investigator in Galectin Therapeutics' Phase 1 clinical trial, shared the data during an oral presentation at the 65 Annual Meeting of the American Association for the Study of Liver Diseases.
GALT: 4.18 (-0.16)
Galectin Therapeutics' Abstract Accepted as Oral Presentation at The Liver Meeting(R), Annual Meeting of the American Association for the Study of Liver Diseases
GlobeNewswire - Wed Oct 01, 12:45PM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company's abstract titled "Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis" was accepted as an oral presentation at The Liver Meeting, the 65th Annual Meeting of the American Association for the Study of Liver Diseases. The presentation will be made on Sunday, November 9, 2014 at 3:30pm Eastern Standard Time at the Hynes Convention Center in Boston, Mass.
GALT: 4.18 (-0.16)
EQUITY ALERT: Rosen Law Firm Reminds Galectin Therapeutics, Inc. Investors of Important September 29, 2014 Class Action Deadline -- GALT
GlobeNewswire - Fri Sep 26, 5:37PM CDT
The Rosen Law Firm, P.A. reminds purchasers of Galectin Therapeutics, Inc. (Nasdaq:GALT) securities between January 6, 2014 and July 28, 2014, of the important September 29, 2014 lead plaintiff deadline in the class action.
GALT: 4.18 (-0.16)
Hagens Berman Reminds Galectin Investors 4 Days Remain in Lead Plaintiff Class-Action Deadline
Marketwire - Thu Sep 25, 10:18AM CDT
Hagens Berman Sobol Shapiro LLP, a top-tier investor-rights law firm, advises investors that there are only four days until the Sept. 29, 2014, lead plaintiff deadline in the securities fraud class action against Galectin Therapeutics Inc. (NASDAQ: GALT) ("Galectin" or "the Company"
. Investors who purchased Galectin shares between January 6, 2014 and July 28, 2014 (the "Class Period" should contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling (510) 725-3000, emailing GALT@hbsslaw.com or visiting http://hb-securities.com/investigations/GALT.
GALT: 4.18 (-0.16)
Galectin Therapeutics appoints Dr. Gilbert S. Omenn to board
M2 - Thu Sep 25, 6:48AM CDT
Therapeutics company Galectin Therapeutics (NasdaqCM :GALT) revealed on Wednesday the addition of Dr. Gilbert S. Omenn, M.D., Ph.D., to its board of directors as well as to its scientific advisory board with immediate effect.
ESPR: 29.10 (-1.67), GALT: 4.18 (-0.16)
Galectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., a Leading Cancer Researcher, to Its Board of Directors
GlobeNewswire - Wed Sep 24, 7:00AM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the election of Gilbert S. Omenn, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Omenn, a leading cancer researcher, is a professor of internal medicine, human genetics and public health, and director of the Center for Computational Medicine and Bioinformatics at the University of Michigan in Ann Arbor, Mich.
GALT: 4.18 (-0.16), AMGN: 164.01 (+1.37)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT
GlobeNewswire - Mon Sep 22, 7:20PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of investors who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company" (Nasdaq:GALT) securities between January 6, 2014 and July 28, 2014.
GALT: 4.18 (-0.16)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Galectin Therapeutics Inc. to Contact Brower Piven Before the September 29, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- GALT
GlobeNewswire - Mon Sep 22, 12:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics Inc. ("Galectin" (Nasdaq:GALT) publicly traded securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" .
GALT: 4.18 (-0.16)
Biotech Stocks Technical Data - Medivation, Galectin Therapeutics, Ironwood Pharma, Achillion Pharma, and PDL BioPharma
PR Newswire - Tue Sep 16, 8:05AM CDT
The US markets on Monday, September 15 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,031.14, up 0.26% and the NASDAQ Composite closed at 4,518.90, down 1.07%. The S&P 500 finished the session 0.07% lower at 1,984.13. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 734.33, down 0.32%, whereas the index has gained 6.67% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Galectin Therapeutics Inc. (NASDAQ: GALT), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and PDL BioPharma Inc. (NASDAQ: PDLI). Free research on these five companies can be accessed at:
MDVN: 107.97 (-1.11), IRWD: 13.63 (+0.42), ACHN: 13.20 (+0.29), GALT: 4.18 (-0.16), PDLI: 7.87 (-0.01)
Galectin Therapeutics wins US patent for GR-MD-02 development programme in diabetic nephropathy
M2 - Tue Sep 16, 6:29AM CDT
Therapeutics company Galectin Therapeutics (NasdaqCM:GALT) reported on Monday the receipt of the patent titled 'Galactose-Pronged Carbohydrate Compounds for the Treatment of Diabetic Nephropathy and Associated Disorders' from the US Patent and Trademark Office.
GALT: 4.18 (-0.16)
GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT
GlobeNewswire - Mon Sep 15, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq:GALT), if they purchased the Company's securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of Nevada.
GALT: 4.18 (-0.16)
Top Swing Trade Ideas for Monday: Cerus, Endocyte, More
at The Street - Mon Sep 15, 9:02AM CDT
Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?
CERS: 4.32 (+0.04), ECYT: 6.34 (+0.04), GALT: 4.18 (-0.16)
Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy
GlobeNewswire - Mon Sep 15, 7:00AM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Patent and Trademark Office has issued a patent for the Company's application titled "Galactose-Pronged Carbohydrate Compounds for the Treatment of Diabetic Nephropathy and Associated Disorders." The patent, assigned U.S. Patent No. 8,828,971, was issued September 9, 2014.
GALT: 4.18 (-0.16)
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
NETE: 1.76 (+0.45), IMDZ: 30.90 (-0.73), EFOI: 5.06 (+0.03), MSON: 11.11 (-0.02), GALT: 4.18 (-0.16), SPOK: 16.03 (+0.31), FUEL: 17.35 (+0.39), LAKE: 10.36 (-0.21), CNVR: 34.89 (+0.01)
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Galectin Therapeutics Inc. Of Upcoming Deadline
Business Wire - Fri Sep 12, 11:19AM CDT
Rigrodsky & Long, P.A.:
GALT: 4.18 (-0.16)
GALT Recent Posts: http://investorshangout.com/Galectin-Therapeu...ALT-61936/
GALT Galectin Therapeutics Inc Recent Headline News
Galectin NASH treatment meets primary endpoint in Phase 1
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:12AM CST
GALT: 4.18 (-0.16)
Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program
GlobeNewswire - Mon Nov 10, 7:43AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third quarter and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission. The Company also provided an update on its development program.
GALT: 4.18 (-0.16)
Galectin Therapeutics beats by $0.10
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:25AM CST
GALT: 4.18 (-0.16)
Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development
GlobeNewswire - Sun Nov 09, 2:30PM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, presented data today from the Company's Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis at The Liver Meeting in Boston, Massachusetts. Stephen A. Harrison, MD, Chief of Hepatology at Brooke Army Medical Center in Fort Sam Houston and a clinical trial investigator in Galectin Therapeutics' Phase 1 clinical trial, shared the data during an oral presentation at the 65 Annual Meeting of the American Association for the Study of Liver Diseases.
GALT: 4.18 (-0.16)
Galectin Therapeutics' Abstract Accepted as Oral Presentation at The Liver Meeting(R), Annual Meeting of the American Association for the Study of Liver Diseases
GlobeNewswire - Wed Oct 01, 12:45PM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company's abstract titled "Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis" was accepted as an oral presentation at The Liver Meeting, the 65th Annual Meeting of the American Association for the Study of Liver Diseases. The presentation will be made on Sunday, November 9, 2014 at 3:30pm Eastern Standard Time at the Hynes Convention Center in Boston, Mass.
GALT: 4.18 (-0.16)
EQUITY ALERT: Rosen Law Firm Reminds Galectin Therapeutics, Inc. Investors of Important September 29, 2014 Class Action Deadline -- GALT
GlobeNewswire - Fri Sep 26, 5:37PM CDT
The Rosen Law Firm, P.A. reminds purchasers of Galectin Therapeutics, Inc. (Nasdaq:GALT) securities between January 6, 2014 and July 28, 2014, of the important September 29, 2014 lead plaintiff deadline in the class action.
GALT: 4.18 (-0.16)
Hagens Berman Reminds Galectin Investors 4 Days Remain in Lead Plaintiff Class-Action Deadline
Marketwire - Thu Sep 25, 10:18AM CDT
Hagens Berman Sobol Shapiro LLP, a top-tier investor-rights law firm, advises investors that there are only four days until the Sept. 29, 2014, lead plaintiff deadline in the securities fraud class action against Galectin Therapeutics Inc. (NASDAQ: GALT) ("Galectin" or "the Company"
. Investors who purchased Galectin shares between January 6, 2014 and July 28, 2014 (the "Class Period" should contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling (510) 725-3000, emailing GALT@hbsslaw.com or visiting http://hb-securities.com/investigations/GALT. GALT: 4.18 (-0.16)
Galectin Therapeutics appoints Dr. Gilbert S. Omenn to board
M2 - Thu Sep 25, 6:48AM CDT
Therapeutics company Galectin Therapeutics (NasdaqCM :GALT) revealed on Wednesday the addition of Dr. Gilbert S. Omenn, M.D., Ph.D., to its board of directors as well as to its scientific advisory board with immediate effect.
ESPR: 29.10 (-1.67), GALT: 4.18 (-0.16)
Galectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., a Leading Cancer Researcher, to Its Board of Directors
GlobeNewswire - Wed Sep 24, 7:00AM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the election of Gilbert S. Omenn, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Omenn, a leading cancer researcher, is a professor of internal medicine, human genetics and public health, and director of the Center for Computational Medicine and Bioinformatics at the University of Michigan in Ann Arbor, Mich.
GALT: 4.18 (-0.16), AMGN: 164.01 (+1.37)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT
GlobeNewswire - Mon Sep 22, 7:20PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of investors who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company"
(Nasdaq:GALT) securities between January 6, 2014 and July 28, 2014. GALT: 4.18 (-0.16)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Galectin Therapeutics Inc. to Contact Brower Piven Before the September 29, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- GALT
GlobeNewswire - Mon Sep 22, 12:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics Inc. ("Galectin"
(Nasdaq:GALT) publicly traded securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . GALT: 4.18 (-0.16)
Biotech Stocks Technical Data - Medivation, Galectin Therapeutics, Ironwood Pharma, Achillion Pharma, and PDL BioPharma
PR Newswire - Tue Sep 16, 8:05AM CDT
The US markets on Monday, September 15 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,031.14, up 0.26% and the NASDAQ Composite closed at 4,518.90, down 1.07%. The S&P 500 finished the session 0.07% lower at 1,984.13. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 734.33, down 0.32%, whereas the index has gained 6.67% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Galectin Therapeutics Inc. (NASDAQ: GALT), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and PDL BioPharma Inc. (NASDAQ: PDLI). Free research on these five companies can be accessed at:
MDVN: 107.97 (-1.11), IRWD: 13.63 (+0.42), ACHN: 13.20 (+0.29), GALT: 4.18 (-0.16), PDLI: 7.87 (-0.01)
Galectin Therapeutics wins US patent for GR-MD-02 development programme in diabetic nephropathy
M2 - Tue Sep 16, 6:29AM CDT
Therapeutics company Galectin Therapeutics (NasdaqCM:GALT) reported on Monday the receipt of the patent titled 'Galactose-Pronged Carbohydrate Compounds for the Treatment of Diabetic Nephropathy and Associated Disorders' from the US Patent and Trademark Office.
GALT: 4.18 (-0.16)
GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT
GlobeNewswire - Mon Sep 15, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq:GALT), if they purchased the Company's securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of Nevada. GALT: 4.18 (-0.16)
Top Swing Trade Ideas for Monday: Cerus, Endocyte, More
at The Street - Mon Sep 15, 9:02AM CDT
Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?
CERS: 4.32 (+0.04), ECYT: 6.34 (+0.04), GALT: 4.18 (-0.16)
Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy
GlobeNewswire - Mon Sep 15, 7:00AM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Patent and Trademark Office has issued a patent for the Company's application titled "Galactose-Pronged Carbohydrate Compounds for the Treatment of Diabetic Nephropathy and Associated Disorders." The patent, assigned U.S. Patent No. 8,828,971, was issued September 9, 2014.
GALT: 4.18 (-0.16)
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
NETE: 1.76 (+0.45), IMDZ: 30.90 (-0.73), EFOI: 5.06 (+0.03), MSON: 11.11 (-0.02), GALT: 4.18 (-0.16), SPOK: 16.03 (+0.31), FUEL: 17.35 (+0.39), LAKE: 10.36 (-0.21), CNVR: 34.89 (+0.01)
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Galectin Therapeutics Inc. Of Upcoming Deadline
Business Wire - Fri Sep 12, 11:19AM CDT
Rigrodsky & Long, P.A.:
GALT: 4.18 (-0.16)
(0)
(0)Galectin Therapeutics Inc (GALT) Stock Research Links
Scroll down for more posts ▼